NextCure to Present at Upcoming Investor Conferences
BELTSVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...
News
Microbot Medical’s Novel LIBERTY® Robotic System Continues to be Validated with Latest U.S. Design Patent Allowance
Advanced Features of Remote Controller Specifically Developed to Deliver an Enhanced User Experience During Endovascular ProceduresHINGHAM, Mass., Nov. 18, 2022...
Venus Concept Announces Completion of $6.72 Million Private Placement Financing
TORONTO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical...
Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer
Established academic and corporate executive with proven track record leading large, multinational organizations across the pharmaceutical and medical device industries...
TrueBinding Announces Results of TB006 Phase 1b/2 Placebo Controlled Proof-of-Concept Trial Showing Improvement on the Primary Cognition and Function Endpoint in Patients with Mild to Severe Alzheimer’s Disease
Top line data from a one-month TB006 treatment regimen shows improvements in Clinical Dementia Rating-Sum of Boxes (CDR-SB) in patients,...
AmMax Bio Announces Oral Presentation of Phase 2 Data of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) at the 2022 CTOS Annual Meeting
Using local administration for a local disease, positive clinical results suggest AMB-05X could become best-in-class treatment for the diverse population...
gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association
ROCKAWAY, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today...
Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended as an early intervention to slow disease progression in patients...
TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants
FORT WORTH, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on...
TeraImmune Presented Research on TREGable™ Technology at HCA Asia 2022
GERMANTOWN, Md., Nov. 18, 2022 (GLOBE NEWSWIRE) -- TeraImmune, Inc., a biotechnology company focused on the discovery and development of...
VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
BRIDGEWATER, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...
Rain Therapeutics to Participate in Piper Sandler’s 34th Annual Healthcare Conference
NEWARK, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision...
Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting
ONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry, which is highly expressed in...
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
VANCOUVER, British Columbia, Nov. 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in...
Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
CAN-3110 designed to limit replication and promote anti-tumor response to tumor cells while protecting healthy tissueNo dose-limiting toxicities observed in...
BBS-Bioactive Bone Substitutes Oyj: The subscription period for the first warrant series starts on 21 November 2022 – the subscription price is EUR 0.92 per share
BBS-Bioactive Bone Substitutes Oyj, Company release, 18 November 2022 at 2.30 p.m. EET BBS-Bioactive Bone Substitutes Oyj (BBS) organized a...
BBS-Bioactive Bone Substitutes – Inside information: The first audit completed by the Notified Body, CE marking process may continue as planned
BBS-Bioactive Bone Substitutes Oyj, Company release, Inside Information, 18 November 2022 at 2.30 p.m. EET The Notified Body has completed...
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)
Phase 2 clinical trial investigating KP1077 in patients with IH expected to initiate prior to year-end 2022 CELEBRATION, Fla., Nov....